

10/590265
IAP9 Rec'd PCT/PTO - 8 AUG 2006

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:	Astrid Netz et al.)	Examiner:	Unknown
)		
Serial No.:	Unassigned)	Group Art Unit:	Unknown
)		
Filed:	08/18/2006)	Confirmation No.	
)		
For:	Guanidine Compounds, and)		
	Use Thereof As Binding)		
	Partners for 5-HT5)		
	Receptors)		

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Attached Form PTO/SB/08A lists references which may be considered to be material to the above-identified application by the Patent Examiner.

Entry into the record is respectfully

requested.

Respectfully submitted

By Martin L. Katz
Martin L. Katz, Reg. No. 25,011

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER
Citigroup Center, Suite 3800
500 West Madison Street
Chicago, Illinois 60661
312/876-1800

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage at First Class Mail in an envelope addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on **August 18, 2006**

Stephanie Frain
Stephanie Frain

<div>Substitute for form 1449A/PTO</div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(Use as many sheets as necessary)</div>				Application Number		Unassigned		
				Filing Date		08/18/2006		
				First Named Inventor		Astrid Netz et al.		
				Group Art Unit		Unknown		
				Examiner Name		Unknown		
Sheet		1	of	2	Attorney Docket No.		ABB10010P02240US	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
		US- 4,560,690 A	12/24/1985	Reiter, Lawrence Alan	

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		JP 09 040671 A	02/10/1997	Fujisawa Pharmaceutical Co., Ltd.		
		JP 08 337579 A	12/24/1996	Fujisawa Pharmaceutical Co. Ltd.		
		JP 08 245621 A	09/24/1996	Fujisawa Pharmaceutical Co., Ltd		
		WO 96/05187 A1	02/22/1996	Fujisawa Pharmaceutical Co., Ltd.		
		WO 95/18126 A1	07/06/1995	Fujisawa Pharmaceutical Co., Ltd.		
		EP 0 545 376 A1	06/09/1993	Fujisawa Pharmaceutical Co., Ltd.		
		WO 92/16526 A1	10/01/1992	Fujisawa Pharmaceutical Co., Ltd.		
		EP 0 259 085 A1	03/09/1988	Pfizer Inc., USA		
		JP 59 036674 A	02/28/1984	Yamanouchi Pharmaceutical Co., Ltd.		
		WO 02/16318 A	02/28/2002	Pacific Corporation		
		WO 99/20599 A	04/29/1999	Cambridge Neuroscience		
		WO 02/36544 A	05/10/2002	Tokuyama Corporation		
		GB 1 031 165 A	05/25/1966	The Wellcome Foundation Ltd.		
Examiner Signature					Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. ⁶ Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	Unassigned
				Filing Date	08/18/2006
				First Named Inventor	Astrid Netz et al.
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	2	of	2	Attorney Docket No.	ABB10010P02240US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KATSURA YOUSUKE ET AL <i>Anti-Helicobacter pylori Agents. 5. 2-(Substituted guanidino)-4-arylthiazoles and Aryloxazole Analogues</i> Journal of Medicinal Chemistry, Vol. 45, No. 1 (2002) pp. 143-150.	
		KATSURA YOUSUKE ET AL <i>Anti-Helicobacter pylori Agents. 4. 2-(Substituted guanidino)-4-phenylthiazoles and Some Structurally Rigid Derivatives</i> Journal of Medicinal Chemistry Vol. 43, No. 17 (2000) pp. 3315-21	
		HOGBERG MARITA ET AL <i>Bioisosteric modification of PETT-HIV-1 RT-inhibitors: synthesis and biological evaluation</i> Bioorganic & Medicinal Chemistry Letter Vol. 10, No. 3 (2000) pp. 265-68	
		KATSURA YOUSUKE ET AL <i>Anti-Helicobacter pylori agents. 3. 2-(Arylalkyl)guanidinol-4-furylthiazoles</i> Journal of Medicinal Chemistry Vol 42, No. 15 (1999) pp. 2920-26	
		GUPTA S ET AL <i>Superpendentic Index: A novel topological descriptor for predicting biological activity</i> Journal of Chemical Information and Computer Sciences Vol 39, No. 2 (1999) pp. 272-77	
		KATSURA YOSUKE ET AL <i>Preparation of furylthiazoles as ulcer inhibitors</i> Doc. No. XO002341494 CAPLUS Chemical Abstracts Service Columbus, OH Database Accession No. 1997:195723	
		KATSURA YOSUKE ET AL <i>Preparation of guanidinothiazole derivatives as histamine H2 antagonists</i> Doc. No. XP002341495 CAPLUS Chemical Abstracts Service Columbus, OH Database Accession No. 1997:140933	
		KAWANISHI YASUYUKI ET AL <i>Synthesis and biological evaluation of a new reversely linked type of dual histamine H2 and gastrin receptor antagonist</i> Doc. No. XP002341496 CAPLUS Chemical Abstracts Service Columbus, OH Database Accession No. 1997:81087	
		Chemical & Pharmaceutical Bulletin Vol. 45, No. 1 (1997) pp. 116-124	
		<i>Preparation of 4-thienylthiazole derivatives as antiulcer and antibacterial agents</i> Doc. No. XP002341497 CAPLUS Chemical Abstracts Service Columbus, OH Database Accession No. 1997:42	
		GOEL ANSHU ET AL <i>Structure-Activity Study on Antiulcer Agents Using Wiener's Topological Index and Molecular Connectivity Index</i> Journal of Chemical Information and Computer Sciences Vol. 35, No. 3 (1995) pp. 504-09	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.